Annexon Biosciences Stock

Biotechnology company developing therapeutics for neurodegenerative and autoimmune disorders

Founded

2011

Headquarters

South San Francisco CA, US

Total Funding

$154M

About Annexon Biosciences Stock

Annexon Biosciences is the development of therapeutic products that halt the progression of complement-mediated neurodegeneration (CMND).

Funding History

August 2011	$1000K
December 2014	$34.0M
June 2016	$44.0M
December 2018	$75.0M

Management

Chief Scientific Officer

Ted Yednock

Co-Founder

Arnon Rosenthal

President & Chief Executive Officer

Douglas Love

Other Companies

Learn More

Arvinas

Arvinas is a pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases.

$112MTotal Funding

Learn More

Bayer

Multinational pharmaceutical and life sciences company

$3.0BTotal Funding

Learn More

Click Therapeutics

Click Therapeutics engineers, validates, and commercializes Digital Therapeutics™ applications

$27.4MTotal Funding

Learn More

Emulate

Emulate, Inc. is a private company focused on commercializing Organs-on-Chips.

$95.0MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Annexon Biosciences or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.